Regulatory approval has now been obtained for all participating coutries.✔️ Since the beginning of the RITA-MI2 trial in 2022, 20 recruitment centres, in France, the UK, Germany, Spain and the Czech Republic have opened for recruitment. 👏 4 additional centres, in...
The RITA-MI2 trial is listed on clinicaltrials.gov, under registration number NCT05211401. Study Description Brief Summary The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left...
For your office, waiting room, conference stands (whenever back in use) or corridors, you have the possibility to download a Poster describing the RITA-MI2 project here. 🖼
